ClinicalTrialsFinder

Acute Myeloid Leukemia With KMT2A Rearrangement Clinical Trials in Cincinnati, Ohio

1 recruitingCincinnati, Ohio

Showing 1–1 of 1 trials

Recruiting
Phase 1

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

Acute Myeloid Leukemia With KMT2A RearrangementAcute Myeloid Leukemia With NPM1 Mutation
National Cancer Institute (NCI)28 enrolled22 locationsNCT05886049